Clinical trials: Neoplasm, Gastrointestinal
Barrett Esophagus
HALO Patient Registry: Ablation of Barrett's Esophagus
The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD).
- Trial name
- NCT00848237
- Testing
- Radiofrequency Ablation (HALO Ablation Systems)
- Where
- United States
- Volunteers
- 5,521 people
- Sponsor
- Medtronic - MITG
Hepatocellular Carcinoma
Surefire Precision Infusion System Registry
This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver…
- Trial name
- NCT02967523
- Testing
- DEB-TACE with Surefire Precision Infusion System
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- Surefire Medical, Inc.
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Pancreatic Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00004861
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Colorectal Cancer, Gastric Cancer
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer.
- Conditions
- Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
- Trial name
- NCT02191761
- Testing
- SM04755
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biosplice Therapeutics, Inc.
Pancreatic Cancer
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, demcizumab (OMP-21M18), when given in combination with gemcitabine with or without (+/-) Abraxane®.
- Trial name
- NCT01189929
- Testing
- Demcizumab, Abraxane®, Gemcitabine
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 57 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Biliary Tract Cancer
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
The term of biliary tract cancer (BTC) or cholangiocarcinoma refers to all tumors that arise from the biliary tract or the biliary drainage system, including the gallbladder.
- Trial name
- NCT03937895
- Testing
- 'SMT-NK' Inj (allogeneic Natural Killer cell), Pembrolizumab Injection [Keytruda]
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- SMT bio Co., Ltd.
Metastatic Colorectal Cancer
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX.
- Trial name
- NCT03035253
- Testing
- OMP-305B83, FOLFIRI, FOLFOX
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumors
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST.
- Trial name
- NCT00135005
- Testing
- AMN107, STI571
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
- Trial name
- NCT00475956
- Testing
- AZD2171, AZD0530
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Barrett Esophagus
Ablation of Intestinal Metaplasia Containing Dysplasia
The purpose of this study is to determine if the intervention of a 510(k)-cleared endoscopically-guided (Halo Ablation systems), ablation system plus anti-secretory therapy is better than anti-secretory therapy alone in clearing…
- Trial name
- NCT00282672
- Testing
- Ablation System plus anti-secretory medication
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- Medtronic - MITG
Advanced Gastrointestinal Cancer
Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
To evaluate the safety and tolerability of MSC_apceth_101.
- Trial name
- TREAT-ME 1 (NCT02008539)
- Testing
- MSC_apceth_101
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Apceth GmbH & Co. KG
GIST - Gastrointestinal Stromal Tumor
Ripretinib (QINLOCK®) According to Current SmPC
The goal of this prospective, observational study INTEREST is to collect real-world data on ripretinib treatment in a broad patient population in Germany. Ripretinib will be administered according to the current SmPC.
- Trial name
- INTEREST (NCT06619275)
- Testing
- Ripretinib
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- iOMEDICO AG
Advanced Gastrointestinal Cancer
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or…
- Trial name
- NCT02024607
- Testing
- BBI608, Fluorouracil, Oxaliplatin
- Where
- 15 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Sumitomo Pharma America, Inc.
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
- Conditions
- Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT02102022
- Testing
- ADI-PEG 20 plus modified FOLFOX6
- Where
- 35 sites in United States, China and 4 more
- Volunteers
- 140 people
- Sponsor
- Polaris Group
Barrett Esophagus
C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.
The primary objective is to determine the safety and efficacy of the C2 CryoBalloon 180 Ablation System ("CryoBalloon 180") used at decreasing doses in ablation naïve patients with low- or high-grade dysplastic Barrett's…
- Trial name
- NCT03311451
- Testing
- C2 CryoBalloon 180° Ablation System
- Where
- 6 sites in Netherlands
- Volunteers
- 62 people
- Sponsor
- Merit Medical Systems, Inc.
Colorectal Cancer, Polyp
Performance Evaluation of the NaviAid™ G-Eye System
The purpose of this study is to compare the additional diagnostic yield obtained by performing NaviAid™ G-Eye procedure vs. the diagnostic yield obtained by performing standard colonoscopy procedure.
- Conditions
- Colorectal Cancer, Polyp, Adenoma
- Trial name
- NCT01552200
- Testing
- Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure, Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy
- Where
- 4 sites in Germany, Israel
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Smart Medical Systems Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.